NCT06796504Recruiting
The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
Source: ClinicalTrials.gov · Last updated 2 Sept 2026
Brief summary (registry, in English)
The MS pilot study will assess the safety and investigate the remyelinating effects of the SetPoint System (study device) in adult patients diagnosed with relapsing-remitting multiple sclerosis (RRMS). The SetPoint System is intended for adjunctive use with standard of care therapy for RRMS. The study device contains a miniaturized stimulator (implant) that is surgically placed under general anesthesia on the vagus nerve through a small incision on the left side of the neck (implant procedure). The study will enroll up to 60 participants at up to 10 sites. All eligible participants will undergo the implant procedure. Two-thirds of the participants will receive active stimulation (treatment) and the one-third will receive non-active stimulation (control). Following treatment evaluations at Week 48, there will be a one-way crossover of control subjects to active stimulation and a 48-week open-label follow-up with all subjects (treatment and control) receiving active stimulation to evaluate long-term safety.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 22 Jan 2025
- Start date
- 17 Apr 2026
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- SetPoint Medical Corporation
- Diseases
- Multiple sclerosis
- NCT number
- NCT06796504
What you commit to
- Study type: Interventional
- Planned participants: 60
- From 17 Apr 2026 to the primary completion date, 31 Dec 2027
- 9 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concurrent neurological disorders, including known moderate or severe cervical myelopathy.
- Clinical optic neuritis within 6 months before screening.
- Steroid treatment for MS symptoms in the 30 days prior to consent
- Not a surgical candidate.
Other illness
- Confounding ophthalmologic disease or impairments/conditions that could interfere with visual testing (e.g., cataracts, disc hemorrhage, macular star, cotton wool spots, macular degeneration, glaucoma, diabetic and/or hypertensive retinopathy, history of detached retina, etc.)
- Hypersensitivity/allergy to MRI contrast agents and/or unable to perform MRI (e.g., claustrophobia).
Other
- Severe myopia defined as a refractive error of -6.00 diopters or more
- Body Mass Index \>40 kg/m2
- Regular use of or dependency on nicotine products within the past year.
Who the study is looking for
- Age 22-60 years at informed consent.
- Diagnosis of RRMS by revised 2017 McDonald criteria.
- MS disease duration does not exceed 15 years from date of diagnosis at the time of informed consent
- Latency delay \>116 milliseconds on baseline full-field transient pattern reversal visual evoked potential (VEP) in at least one eye. Both eyes can be included if they meet all inclusion criteria.Patients who do not meet the absolute P100 latency threshold of 116 ms in either eye will qualify if they have an inter-eye difference in P100 latency of \>6 ms
- Peri-papillary retinal nerve fiber layer (pRNFL) \> 70 microns on Optical Coherence Topography (OCT) in the VEP-qualifying eye (sufficient axons).
- Best corrected high-contrast (HCVA) better than 20/200 Snellen equivalent or letter score of 35
- Best corrected low-contrast letter acuity (LCLA) by Sloan chart (2.5% black on white) of no better than 40 letters in the VEP-qualifying eye (Snellen equivalent of 20/40). (Best corrected LCLA must be worse than best corrected HCVA.)
- Absence of clinical relapse for at least 12 months prior to informed consent
- No new lesions or increase in existing lesion volume on most recent clinic brain MRI (must be within 1 year of consent)
- Taking a stable regimen of disease-modifying therapy (DMT) prior to informed consent. The DMT must have been started and maintained at least one year prior to consent.
- Score of 2.5 to 6.5 by Expanded Disability Status Scale (EDSS) at baseline.
Age in the registry: 22 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (9)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shepherd Center Coordinator of this site? Confirm its status | Atlanta | United States | Recruiting |
| The University of Texas at Austin Coordinator of this site? Confirm its status | Austin | United States | Recruiting |
| Johns Hopkins School of Medicine Coordinator of this site? Confirm its status | Baltimore | United States | Recruiting |
| The University of Texas Health Science Center at Houston Coordinator of this site? Confirm its status | Houston | United States | Recruiting |
| University of California Irvine Center for Clinical Research Coordinator of this site? Confirm its status | Irvine | United States | Recruiting |
| Medical College of Wisconsin Coordinator of this site? Confirm its status | Milwaukee | United States | Recruiting |
| West Virginia University Coordinator of this site? Confirm its status | Morgantown | United States | Recruiting |
| Minnesota Center for Multiple Sclerosis Coordinator of this site? Confirm its status | Plymouth | United States | Recruiting |
| UW Medicine Multiple Sclerosis Center-Northwest Coordinator of this site? Confirm its status | Seattle | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.